All News

Article

Update on Polymyalgia Rheumatica and Giant Cell Arteritis (Best of 2020)

Jack Cush, MD Dec 31, 2020

JAMA has published a clinical update of recent studies on GCA. While PET/CT scanning are novel means of demonstrating activity, they have not changed the diagnostic approach to GCA or PMR and although there are no new proven treatment strategies for PMR beyond glucocorticoids, the FDA has approved tocilizumab as a first-line glucocorticoid-sparing agent.

Article

The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis

Richard Conway, MBBChBAO, PhD Nov 30, 2020

Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events.

#Bestof2020 Update on Polymyalgia Rheumatica and Giant Cell Arteritis https://t.co/8Kxts1X43H https://t.co/j06SFRxQ3m

https://bit.ly/2Lm4CBL

Plasmapheresis Indications : TTP, HUS, Cryoglobulinemia, Hyperviscosity, Myasthenia gravis, Goodpastures, Catastrophic APL Syn, Chr inflamm demyelinating polyneuropathy, Removal of drugs/toxins, Alveolar hemorrhage, ANCA vasculitis (questionable) https://t.co/8TBExIx0Kx

https://bit.ly/34XZo6p

#BestACR20Tweets RT @RichardPAConway : Really important study by @SattuiSEMD on high prevalence of frailty and its impact on QOL in PMR #ACR20 @rheumnow Abstr#422 https://t.co/QzDYGsqDeJ

Check out our latest article from Richard Conway ( @RichardPAConway) #ACR20 The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis https://t.co/VG1ah3Nq5c https://t.co/js3l527VHg

https://bit.ly/2UvUk3G

Imaging and Large Vessel Vasculitis: Dr. Alexa S. Meara interviews Dr. Kaitlin Quinn #ACR20 https://t.co/CWN2C1P6Fz https://t.co/yHg63VPkiW

https://bit.ly/33UqVVZ

#BestACR20Tweets RT @RHEUMarampa : Novel predictors of early mortality in a cohort of GCA pts from Portugal: 🚩Older age at dx 🚩Tongue claudication 🚩Prior tx w/ anticoag BP treatment at dx - predictor of early survival. @RheumNow #ACR20 abs1935 https://t.co/vCi2gMCmKE https://t.co/HuTv1p8Yua

https://bit.ly/36rcUAA

#BestACR20Tweets RT @RichardPAConway :Dr Cid presents phase 2 trial of anti-GM-CSF agent mavrilimumab in combination with steroids in GCA. 70 patients. Sustained remission at week 26 in 83.2% of mavrilimumab vs 49.9% of placebo p=0.0038. @DrPujaMehta1 #ACR20 Abstr#L06 https://t.co/ynWbguXXzR

#BestACR20Tweets RT @SattuiSEMD :L06: Mavrilimumab in #GCA Efficacy+safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV Sustained remission➡️ 33% ⬆️ in MAV No diff in new/relapsing/ref pts, No diff in AE

#BestACR20Tweets RT @doctorRBC : Mavrilimumab efficacious in maintaining disease remission in GCA pts. Phase 2 trial (n=70) Disease flare 19% in tx vs. 46% in PBO at 26wk Sustained remission 83% vs. 50% in PBO Similar AE in both groups Abs#L06 https://t.co/fsZxZVmDIu" https://t.co/j17naatAxX

https://bit.ly/2J6XfNZ

#BestACR20Tweets RT @drdavidliew : Mavrilimumab (anti-GM-CSF) in GCA, phase 2 GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying?? PNL induction then enrol+PNL taper GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62% ABSTL06 https://t.co/xxjd2lTSUe https://t.co/uuBOnbk6Ab

https://bit.ly/362tUgu

#BestACR20Tweets RT @DrPetryna: #ACR20 prosp cohort study of angiographic lesions in Takayasu’ GCA:new angio lesions more likely in TAK.Improvement possible in both conditions, more likely in TAK.Change in the branch arteries more dynamic than in the aorta https://t.co/iC0TJ08Tsr https://t.co/Y1hIDGJ9Ro

https://bit.ly/36Y6ecq

#BestACR20Tweets RT @DrPetryna : @RheumNow #ACR20 abs1921 single center baseline & follow-up PET/CT scan study in pts w/ refractory LVV-GCA on TCZ: while 83.33%pts achieved clincial remission only 10% experiences normalization of Total vascular score. https://t.co/M97X8fLfLp

https://bit.ly/32YwQZi

#BestARC20Tweets "RT @drdavidliew : Great to sit down with @LCalabreseDO @Sarah_L_Mackie @RichardPAConway a few hours ago and chat about two very interesting GCA therapeutics abstracts: https://t.co/V3fzB0W3Ko great discussion! #ACR20 @RheumNow"

https://bit.ly/3lMUpf3

Read our article titled: Best Imaging Techniques for non ANCA Vasculitis by Dr. Alexa Meara ( @lexmeara) as discussed at #ACR20 https://t.co/CyfC8bdq42 https://t.co/Ay7Sw0eMTY

https://bit.ly/3f147rE

"The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis" by Dr. Richard Conway ( @RichardPAConway) https://t.co/VG1ah3Nq5c https://t.co/jORhfQn3EC

https://bit.ly/2UvUk3G

Avacopan - C5a Receptor Inhibitor - in ANCA-Associated Vasculitis: Dr. Arthur Kavanaugh #ACR20 https://t.co/kJxdgoL5EI https://t.co/uYUwUr53lL

https://bit.ly/3ltrlZU

Read our article titled: Best Imaging Techniques for non ANCA Vasculitis by Dr. Alexa Meara ( @lexmeara) as discussed at #ACR20 https://t.co/CyfC8bdq42 https://t.co/HrMGvqcNC4

https://bit.ly/3f147rE

San Diego-based rheumatologist Dr. Arthur Kavanaugh takes a closer look at Avacopan - C5a Receptor Inhibitor - in ANCA-Associated Vasculitis #ACR20. https://t.co/53gQ0dLjU7

https://bit.ly/32vJfDU

Topics

All News

Update on Polymyalgia Rheumatica and Giant Cell Arteritis (Best of 2020)

The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis

Do you get our email newsletter?